Multicenter phase 1 study of garsorasib for non-small cell lung cancer with G12C mutated KRAS

Garsorasib (D-1553) is an orally available potent and selective inhibitor of KRAS^G12C. A multicenter phase 1 study in China evaluated garsorasib for KRAS^G12C mutated NSCLC. Most of the adverse events were manageable, and the patients tolerated the study treatment well. Among the patients evaluable for response at the recommended phase 2 dose (garsorasib 600 mg twice daily), the ORR was 38.7% and the DCR was 90.3%, with median DOR and PFS of 6.9 months and 7.6 months, respectively. The authors conclude that garsorasib is a promising therapeutic option for patients with KRAS G12C-mutated NSCLC.